Skip to main content

Advertisement

SpringerLink
Log in

What oncologists need and require from nuclear medicine

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450(7171):893–8.

    Article  PubMed  CAS  Google Scholar 

  2. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, et al. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western array and immunohistochemistry. Cancer Res 2006;66:11194–206.

    Article  PubMed  CAS  Google Scholar 

  3. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet 2002;32 Suppl:533–40.

    Article  PubMed  Google Scholar 

  4. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007;25:5418–25.

    Article  PubMed  Google Scholar 

  5. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772–8.

    Article  PubMed  CAS  Google Scholar 

  6. Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 2005;8:269–71.

    Article  PubMed  CAS  Google Scholar 

  7. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25:675–80.

    Article  PubMed  CAS  Google Scholar 

  8. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2007;25:146–62.

    Article  PubMed  CAS  Google Scholar 

  9. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325–31.

    Article  PubMed  CAS  Google Scholar 

  10. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007;25(18S):4000. ASCO Annual Meeting Proceedings Part I, June 20 Supplement.

    Google Scholar 

  11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005;353:1659–72.

    Article  PubMed  CAS  Google Scholar 

  12. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005;353:1673–84.

    Article  PubMed  CAS  Google Scholar 

  13. DeMatteo R, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol 2007;25:18S. abstr 10079.

    Google Scholar 

  14. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37.

    Article  PubMed  CAS  Google Scholar 

  15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non small-cell lung cancer. N Engl J Med 2005;353:123–32.

    Article  PubMed  CAS  Google Scholar 

  16. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–90.

    Article  PubMed  CAS  Google Scholar 

  17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  18. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773–82.

    Article  PubMed  CAS  Google Scholar 

  19. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753–9.

    Article  PubMed  Google Scholar 

  20. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference. J Nucl Med 2007;48:36S–44S.

    Article  PubMed  CAS  Google Scholar 

  21. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803–10.

    Article  PubMed  CAS  Google Scholar 

  22. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279–86.

    Article  PubMed  CAS  Google Scholar 

  23. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914–21.

    Article  PubMed  CAS  Google Scholar 

  24. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166–9.

    Article  PubMed  Google Scholar 

  25. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab–irinotecan therapy. J Clin Oncol 2007;25:3930–5.

    Article  PubMed  CAS  Google Scholar 

  26. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.

    Article  PubMed  CAS  Google Scholar 

  27. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.

    Article  PubMed  CAS  Google Scholar 

  28. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–29.

    Article  PubMed  CAS  Google Scholar 

  29. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.

    Article  PubMed  CAS  Google Scholar 

  30. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 2008;34:103–21.

    Article  PubMed  CAS  Google Scholar 

  31. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34:850–8.

    Article  PubMed  CAS  Google Scholar 

  32. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008;in press.

  33. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 2005;48:5337–48.

    Article  PubMed  CAS  Google Scholar 

  34. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006;8:262–77.

    Article  PubMed  CAS  Google Scholar 

  35. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–6.

    Article  PubMed  CAS  Google Scholar 

  36. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006;47:793–6.

    PubMed  CAS  Google Scholar 

  37. Pantaleo MA, Fanti S, Lollini PL, Boschi S, Biasco G. PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment. Eur J Nucl Med Imaging 2007;34:1510–1.

    Article  CAS  Google Scholar 

  38. Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007;34:153–63.

    Article  PubMed  CAS  Google Scholar 

  39. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 2002;62:5912–9.

    PubMed  CAS  Google Scholar 

  40. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. Oncologist 2008;13:25–38.

    Article  PubMed  CAS  Google Scholar 

  41. Nanni C, Rubello D, Fanti S. Role of small animal PET for molecular imaging in pre-clinical studies. Eur J Nucl Med Mol Imaging 2007;34:1819–22.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Hematology and Medical Oncology “L.A. Seragnoli”, Sant’Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy

    M. A. Pantaleo, M. Nannini, A. Maleddu & G. Biasco

  2. Nuclear Medicine Service, ‘Sant’Orsola-Malpighi’ Hospital, University of Bologna, Bologna, Italy

    S. Fanti & C. Nanni

  3. PET Radiopharmacy–Nuclear Medicine Service, ‘Sant’Orsola-Malpighi’ Hospital, University of Bologna, Bologna, Italy

    S. Boschi

  4. Department of Nuclear Medicine–PET Centre, ‘S. Maria della Misericordia’ Hospital, Istituto Oncologico Veneto (IOV)-IRCCS, Rovigo, Italy

    D. Rubello

Authors
  1. M. A. Pantaleo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Fanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Nannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Boschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Nanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Maleddu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Rubello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Biasco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. A. Pantaleo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pantaleo, M.A., Fanti, S., Nannini, M. et al. What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging 35, 1761–1765 (2008). https://doi.org/10.1007/s00259-008-0825-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-0825-y

Keywords

Search

Navigation